Lipomatous Tumors Panel

Test Information

This is a comprehensive panel testing for gains, losses and LOH in the liposarcoma specimens along with TP53 targeted mutation analyses. The test is performed in somatic tissue testing via the OncoScan assay; it can identify chromothripsis (genomic instability in the tumor specimens) and copy number gains, losses and LOH of the ALT tumor associated markers along with TP53 hotspot mutation testing analyses. Data analysis, interpretation and reporting are performed adhering to the ACMG clinical laboratory standards for microarray analysis for neoplastic specimens and next-generation sequencing (Genetics in Medicine (2013) 15(9): 733-747).

Turnaround Time

10 days

CPT Code(s)

81406

Cost

$1,000

Clinical Information

Liposarcomas are among the most common soft tissue sarcomas with an incidence rate of 0.4-1.1 per 100,000 people depending on gender and race. This heterogeneous group of neoplasms is classified into various categories depending on histology, molecular signature, and behavior. Liposarcomas can be: 1) well-differentiated/atypical lipomatous tumors 2) dedifferentiated 3) myxoid (round cell) or 4) pleomorphic. Since the first consistent chromosomal aberration was reported in 1986, cyto- and molecular genetic techniques have been integral in characterizing these tumors.

Indications

Gene sequencing and targeted mutation testing and copy number analysis can serve as a useful diagnostic and potentially prognostic tool for the analysis of affected tissues or tumors. The detection of copy number variants or specific gene mutations may enhance treatment decisions.

Specimen Requirements

Analysis can be performed on fresh or frozen tissue samples as well as formalin-fixed, paraffin-embedded tissue samples.

Transport Instructions

The specimen should be kept at the appropriate temperature and delivered via overnight shipping.

Have Questions Need Support?

Call our laboratory at 1-800-473-9411 or contact one of our Laboratory Genetic Counselors for assistance.
Robin Fletcher, MS, CGC
Kellie Walden, MS, CGC

Oncology Testing, Panel
Lucy's Story

Lucy's Story

When our daughter Lucy had a metabolic crisis at 7 days old, we were shocked and devastated to find out that she was born with a rare genetic disorder (MSUD). Her newborn screening results did not make it back in time to prevent the crisis, and no one at our local hospital was familiar with the disease. They did not know how to treat her. Calls were made to Greenwood Genetic Center to confirm her diagnosis...

In The News